{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:20:08Z","timestamp":1790886008211,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rare pathogenic variants in the <jats:italic>PTPN11, KRAS, SOS1<\/jats:italic> and <jats:italic>RAF1<\/jats:italic> genes are the main molecular causes of Noonan syndrome (NS). Most are dominant gain-of-function variants that cause an overactivation of the RAS\/MAPK signaling pathway leading to uncontrolled cell proliferation in many organs and systems. Albeit phenotypically heterogeneous, NS can be associated with severe cardiovascular and lymphatic anomalies, potentially lethal during infancy, neonatal and fetal periods. MEK inhibitors, a class of drugs targeting the final steps of the RAS\/MAPK pathway and originally developed for cancer therapy, have been tested in preclinical studies as a targeted treatment for NS. These studies led to the occasional off-label use of MEK inhibitors in patients with RASopathies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report the case of a preterm infant with congenital pulmonary lymphangiectasis, chylothorax and hypoxic respiratory failure refractory to conventional management, who was treated with trametinib after identification of a NS <jats:italic>PTPN11<\/jats:italic> class 5 variant. We performed a systematic review of the current published evidence on trametinib efficacy and safety for severe respiratory and\/or cardiac manifestations in infants and children with Noonan syndrome, querying PubMed, Embase, Cochrane and Scopus databases, following the PRISMA guideline for systematic reviews, and using the Joanna Briggs Institute (JBI) Critical Appraisal tool for quality assessment of published evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our patient, a five-week trametinib course, maximum dose 0.025 mg\/kg\/day, led to chylothorax resolution and gradual pulmonary function improvement, allowing extubation to non-invasive support, discharge home at a corrected age of 4 months, and weaning off home oxygen therapy by 10 months. No formal clinical trial of trametinib in neonatal\/pediatric Noonan syndrome has been published to our knowledge. We collected 16 published cases, and added this case for reviewing trametinib regimen, efficacy and safety. A short-term improvement of symptoms was reported in all cases, with three deaths presumably unrelated to trametinib. Moderate side effects were reported in a subset of patients. Long-term follow-up data were not available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Trametinib is a promising drug in NS. Clinical trials are warranted to establish safety, efficacy, and standardized protocols for the use of trametinib as a rescue therapy in critically ill children and explore its potential place in the treatment of various NS comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>clinicaltrials.gov<\/jats:uri>, identifier [NCT06555237].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1475143","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:54:25Z","timestamp":1739861665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Isabel","family":"De Brouchoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lorand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9on","family":"Bofferding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sorlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Danhaive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1542\/peds.2009-3207","article-title":"Noonan syndrome: clinical features, diagnosis, and management guidelines","volume":"126","author":"Romano","year":"2010","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajmg.1320530213","article-title":"Clinical and molecular studies in a large Dutch family with noonan syndrome","volume":"53","author":"van der Burgt","year":"1994","journal-title":"Am J Med Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/cge.14309","article-title":"Diagnostic yield from prenatal exome sequencing for non-immune hydrops fetalis: a systematic review and meta-analysis","volume":"103","author":"Al-Kouatly","year":"2023","journal-title":"Clin Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1750-1172-2-4","article-title":"Noonan syndrome","volume":"2","author":"van der Burgt","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.bj.2021.06.004","article-title":"RASopathies: from germline mutations to somatic and multigenic diseases","volume":"44","author":"Riller","year":"2021","journal-title":"Biomed J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00431-023-05263-y","article-title":"Novel therapeutic perspectives in noonan syndrome and RASopathies","volume":"183","author":"Saint-Laurent","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ajmg.a.62529","article-title":"Genotype-cardiac phenotype correlations in a large single-center cohort of patients affected by RASopathies: clinical implications and literature review","volume":"188","author":"Leoni","year":"2022","journal-title":"Am J Med Genet A"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/archdischild-2021-322858","article-title":"Noonan syndrome: improving recognition and diagnosis","volume":"107","author":"Zenker","year":"2022","journal-title":"Arch Dis Child"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/jcm11113128","article-title":"Lymphatic phenotype of noonan syndrome: innovative diagnosis and possible implications for therapy","volume":"11","author":"Kleimeier","year":"2022","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000517605","article-title":"Lymphatic abnormalities in noonan syndrome Spectrum disorders: a systematic review","volume":"13","author":"Sleutjes","year":"2022","journal-title":"Mol Syndromol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1002\/ajmg.a.62955","article-title":"Lymphatic anomalies during lifetime in patients with noonan syndrome: retrospective cohort study","volume":"188","author":"Swarts","year":"2022","journal-title":"Am J Med Genet A"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41436-020-01093-7","article-title":"When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort","volume":"23","author":"Scott","year":"2021","journal-title":"Genet Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/jmedgenet-2018-105746","article-title":"Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era","volume":"56","author":"Stuurman","year":"2019","journal-title":"J Med Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/humu.23624","article-title":"Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework","volume":"39","author":"Grant","year":"2018","journal-title":"Hum Mutat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/genes13010006","article-title":"MEK inhibition in a newborn with RAF1-associated noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease","volume":"13","author":"Mussa","year":"2021","journal-title":"Genes (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41431-020-00708-6","article-title":"Variants of SOS2 are a rare cause of noonan syndrome with particular predisposition for lymphatic complications","volume":"29","author":"Lissewski","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12887-022-03804-2","article-title":"New insights on noonan syndrome\u2019s clinical phenotype: a single center retrospective study","volume":"22","author":"Baldo","year":"2022","journal-title":"BMC Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ajmg.c.32024","article-title":"New prospectives on treatment opportunities in RASopathies","volume":"190","author":"Gelb","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"a031492","DOI":"10.1101\/cshperspect.a031492","article-title":"Targeting the MAPK pathway in RAS mutant cancers","volume":"8","author":"Hymowitz","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1172\/JCI43910","article-title":"Activation of multiple signaling pathways causes developmental defects in mice with a noonan syndrome-associated Sos1 mutation","volume":"120","author":"Chen","year":"2010","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16395","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I recapitulates noonan syndrome in mice","volume":"111","author":"Hernandez-Porras","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15436","DOI":"10.1073\/pnas.0903302106","article-title":"Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations","volume":"106","author":"Nakamura","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","first-page":"dmm049107","DOI":"10.1242\/dmm.049107","article-title":"The RASopathies: from pathogenetics to therapeutics","volume":"15","author":"Hebron","year":"2022","journal-title":"Dis Model Mech"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI63034","article-title":"Endothelial ERK signaling controls lymphatic fate specification","volume":"123","author":"Deng","year":"2013","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"ytad190","DOI":"10.1093\/ehjcr\/ytad190","article-title":"Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with noonan syndrome: case report","volume":"7","author":"Hribernik","year":"2023","journal-title":"Eur Heart J Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/genes13091503","article-title":"Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with noonan syndrome and SOS1 mutation","volume":"13","author":"Lioncino","year":"2022","journal-title":"Genes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"DGPK-eP4","DOI":"10.1055\/s-0041-1725911","article-title":"MEK-inhibition treatment with trametinib in a 7.7-year-old girl with noonan\u2019s syndrome and life-threatening lymphangiopathy","volume":"69","author":"Hofbeck","year":"2021","journal-title":"Thorac Cardiovasc Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101063","article-title":"P166: MEK inhibitor therapy for lymphatic malformations: a focused approach in patients with RASopathies","volume":"2","author":"Taliercio","year":"2024","journal-title":"Genet Med Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101704","DOI":"10.1016\/j.ppedcard.2024.101704","article-title":"MEK inhibition in noonan syndrome patient with severe cardiovascular and lymphatic disease","volume":"72","author":"Torok","year":"2024","journal-title":"Prog Pediatr Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e003327","DOI":"10.1161\/CIRCGEN.121.003327","article-title":"Molecular management of multifocal atrial tachycardia in noonan\u2019s syndrome with MEK1\/2 inhibitor trametinib","volume":"14","author":"Meisner","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104630","DOI":"10.1016\/j.ejmg.2022.104630","article-title":"Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related noonan syndrome","volume":"65","author":"Leegaard","year":"2022","journal-title":"Eur J Med Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/children11111342","article-title":"Refractory chylothorax and ventricular hypertrophy treated with trametinib in a patient with noonan syndrome: 18-month follow-up","volume":"11","author":"Pascarella","year":"2024","journal-title":"Children"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e9164","DOI":"10.1002\/ccr3.9164","article-title":"Trametinib restores the central conducting lymphatic flow in a premature infant with noonan syndrome","volume":"12","author":"Leenders","year":"2024","journal-title":"Clin Case Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.ejhg.5200935","article-title":"Spectrum of mutations in PTPN11 and genotype\u2013phenotype correlation in 96 patients with noonan syndrome and five patients with cardio-facio-cutaneous syndrome","volume":"11","author":"Musante","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-23-1376","article-title":"Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: a report from the children\u2019s oncology group","volume":"142","author":"Stieglitz","year":"2024","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2023.02.010","article-title":"MEK inhibition improves cardiomyopathy in costello syndrome","volume":"81","author":"Geddes","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pediatrneurol.2023.08.019","article-title":"Treatment of refractory epilepsy with MEK inhibitor in patients with RASopathy","volume":"148","author":"D'Onofrio","year":"2023","journal-title":"Pediatr Neurol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.10.002","article-title":"Impact of MEK inhibition on childhood RASopathy-associated hypertrophic cardiomyopathy","author":"Wolf","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.2147\/OTT.S72951","article-title":"Trametinib: a MEK inhibitor for management of metastatic melanoma","volume":"8","author":"Lugowska","year":"2015","journal-title":"Onco Targets Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/life14060731","article-title":"Exploring new drug repurposing opportunities for MEK inhibitors in RASopathies: a comprehensive review of safety, efficacy, and future perspectives of trametinib and selumetinib","volume":"14","author":"Gazzin","year":"2024","journal-title":"Life"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e30190","DOI":"10.1002\/pbc.30190","article-title":"Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy","volume":"70","author":"Chan","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cjca.2024.02.020","article-title":"MEK inhibition for RASopathy-associated hypertrophic cardiomyopathy: clinical application of a basic concept","volume":"40","author":"Chaput","year":"2024","journal-title":"Can J Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.117.028351","article-title":"Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension","volume":"136","author":"Hadinnapola","year":"2017","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00383-015-3678-z","article-title":"Pulmonary capillary hemangiomatosis in a neonate with congenital diaphragmatic hernia","volume":"31","author":"Akinkuotu","year":"2015","journal-title":"Pediatr Surg Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-015-1754-3","article-title":"Relapsing pneumonitis due to two distinct inhibitors of the MAPK\/ERK pathway: report of a case","volume":"15","author":"Giraud","year":"2015","journal-title":"BMC Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","article-title":"Outcomes in children with noonan syndrome and hypertrophic cardiomyopathy: a study from the pediatric cardiomyopathy registry","volume":"164","author":"Wilkinson","year":"2012","journal-title":"Am Heart J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK network as a therapeutic target in human cancer","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ejhg.2012.285","article-title":"Prenatal diagnostic testing of the noonan syndrome genes in fetuses with abnormal ultrasound findings","volume":"21","author":"Croonen","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/pd.2804","article-title":"Prenatal features of noonan syndrome: prevalence and prognostic value","volume":"31","author":"Baldassarre","year":"2011","journal-title":"Prenatal Diagnosis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMoa2023643","article-title":"Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis","volume":"383","author":"Sparks","year":"2020","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/jp.2017.150","article-title":"Prenatal factors associated with neonatal survival of infants with congenital chylothorax","volume":"38","author":"Dorsi","year":"2018","journal-title":"J Perinatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"S299","DOI":"10.21037\/cdt.2019.05.01","article-title":"Long-term outcomes of childhood onset noonan compared to sarcomere hypertrophic cardiomyopathy","volume":"9","author":"Kaltenecker","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"100248","DOI":"10.1016\/j.esmoop.2021.100248","article-title":"Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy","volume":"6","author":"Hassel","year":"2021","journal-title":"ESMO Open"},{"key":"B63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2014.5559","article-title":"How to read a systematic review and meta-analysis and apply the results to patient care","volume":"312","author":"Murad","year":"2014","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5306\/wjco.v7.i2.253","article-title":"Off-label use of targeted therapies in oncology","volume":"7","author":"Lev\u00eaque","year":"2016","journal-title":"World J Clin Oncol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1475143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:54:27Z","timestamp":1739861667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1475143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":64,"alternative-id":["10.3389\/fped.2025.1475143"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1475143","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1475143"}}